MISMATCH REPAIR DEFICIENT COLORECTAL CANCER
Clinical trials for MISMATCH REPAIR DEFICIENT COLORECTAL CANCER explained in plain language.
Never miss a new study
Get alerted when new MISMATCH REPAIR DEFICIENT COLORECTAL CANCER trials appear
Sign up with your email to follow new studies for MISMATCH REPAIR DEFICIENT COLORECTAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill takes on brain tumors and metastases in early trial
Disease control Recruiting nowThis study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…
Matched conditions: MISMATCH REPAIR DEFICIENT COLORECTAL CANCER
Phase: PHASE1, PHASE2 • Sponsor: Neonc Technologies, Inc. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Immunotherapy before surgery shows promise for certain colorectal cancers
Disease control Recruiting nowThis trial is testing whether giving the immunotherapy drug pembrolizumab before surgery can improve outcomes for people with high-risk stage 2 or stage 3 colorectal cancer that has a specific genetic feature called mismatch repair deficiency. About 88 participants will receive p…
Matched conditions: MISMATCH REPAIR DEFICIENT COLORECTAL CANCER
Phase: PHASE2 • Sponsor: University College, London • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC